Fish; Fish Eggs; Shell Fish; Crustacea Patents (Class 530/857)
  • Patent number: 8367355
    Abstract: Disclosed are an antigen protein of black-lip pearl oyster egg extract, an antibody specific thereto, and a method of quantitative assessment of the reproductive effort of black-lip pearl oyster using the antibody. The method accomplishes quantitative assessment of reproductive effort of black-lip pearl oysters easily and accurately. In addition, the method provides important information for the study of life cycles of black-lip pearl oysters, and allows efficient management of black-lip pearl oysters.
    Type: Grant
    Filed: April 13, 2010
    Date of Patent: February 5, 2013
    Assignee: Korea Ocean Research And Development Institute
    Inventors: Do Hyung Kang, Kwang Sik Choi, Hee Do Jeoung, Heung Sik Park
  • Patent number: 8110549
    Abstract: The invention relates to relatively short peptides (termed ?-conotoxins herein), about 10-30 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds.
    Type: Grant
    Filed: March 8, 2011
    Date of Patent: February 7, 2012
    Assignee: University of Utah Research Foundation
    Inventors: Maren Watkins, Baldomero M. Olivera, David R. Hillyard, J. Michael McIntosh, Robert M. Jones
  • Patent number: 8101573
    Abstract: The invention relates to novel conopeptides and/or novel uses of conopeptides. The conopeptides of the invention are analogs of ?-Conotoxin MII that are selective for ?6-containing nAChRs as described herein.
    Type: Grant
    Filed: June 4, 2008
    Date of Patent: January 24, 2012
    Assignee: University of Utah Research Foundation
    Inventor: J. Michael McIntosh
  • Patent number: 7902153
    Abstract: The invention relates to relatively short peptides (termed ?-conotoxins herein), about 10-30 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds.
    Type: Grant
    Filed: February 17, 2010
    Date of Patent: March 8, 2011
    Assignee: University of Utah Research Foundation
    Inventors: Maren Watkins, Baldomero M. Olivera, David R. Hillyard, J. Michael McIntosh, Robert M. Jones
  • Patent number: 7666840
    Abstract: The invention relates to relatively short peptides (termed ?-conotoxins herein), about 10-30 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds.
    Type: Grant
    Filed: October 9, 2007
    Date of Patent: February 23, 2010
    Assignees: The University of Utah Research Foundation, Cognetix, Inc.
    Inventors: Maren Watkins, Baldomero M. Olivera, David R. Hillyard, J. Michael McIntosh, Robert M. Jones
  • Publication number: 20090036656
    Abstract: A method of preparing a biomaterial comprises steps of acellularizing the fish scale, decalcifying the fish scale, and cleaning the fish scale and then extruding the fish scales.
    Type: Application
    Filed: April 9, 2008
    Publication date: February 5, 2009
    Applicant: BODY ORGAN BIOMEDICAL CORP.
    Inventors: Horng-Ji LAI, Chien-Cheng LIN, Shang-Ming LIN
  • Patent number: 7387997
    Abstract: The invention relates to novel conopeptides and/or novel Luses of conopeptides. The conopeptides of the invention are analogs of ?-Conotoxin MII that are selective for ?6-containing nAChRs as described herein.
    Type: Grant
    Filed: November 9, 2005
    Date of Patent: June 17, 2008
    Assignee: University of Utah
    Inventor: J. Michael McIntosh
  • Patent number: 7381706
    Abstract: A novel peptide found as gonadotropin-releasing hormone (GnRH) in octopuses, a member of mollusks. The structure and the activities of the peptide have been unraveled. The peptide finds use as a reagent used in the studies of correlations between the structure and the activities of GnRH and the information processing mechanisms of the nervous systems in higher animals. It can also serve as a base compound in the development of pesticides and drugs. The peptide has the GnRH activity and has the following amino acid sequence (I): <Glu-Zaa-Zaa-His-Zaa-Ser-Zaa-Zaa-Zaa-Zaa-Pro-Gly-NH2 (SEQ ID NO: 7) ??(I) wherein <Glu represents pyroglutamic acid and Zaa represents any amino acid. Specifically, the peptide has the following amino acid sequence (1): <Glu-Asn-Tyr-His-Phe-Ser-Asn-Gly-Trp-His-Pro-Gly-NH2 (SEQ ID NO: 1) ??(1) wherein <Glu represents pyroglutamic acid.
    Type: Grant
    Filed: June 29, 2001
    Date of Patent: June 3, 2008
    Assignee: Suntory Limited
    Inventors: Hiroyuki Minakata, Eiko Iwakoshi, Kyoko Kuroda
  • Patent number: 7368432
    Abstract: The invention relates to relatively short conotoxin peptides, about 10-20 residues in length as described herein, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds. These conotoxin peptides have analgesic activity and are thus useful for treating or preventing pain.
    Type: Grant
    Filed: July 19, 2004
    Date of Patent: May 6, 2008
    Assignees: Xenome, Ltd., Cognetix, Inc.
    Inventors: J. Michael McIntosh, Baldomero M. Olivera, Lourdes J. Cruz, Gloria P. Corpuz, Robert M. Jones, James E. Garrett
  • Patent number: 7358332
    Abstract: Novel bioactive peptide compositions and process for producing the same and the use of such compositions for enhancing the growth of warm blooded animals and fish is disclosed.
    Type: Grant
    Filed: May 19, 2004
    Date of Patent: April 15, 2008
    Assignee: Seagarden AS
    Inventors: Jan Raa, Gunnar Rorstad
  • Patent number: 7351693
    Abstract: The invention relates to anti-microbial and immunostimulatory molecules of the cathelicidin family derived from fish. The invention provides a novel cathelicidin molecule, fragments, derivatives and uses thereof, and nucleic acids encoding the same.
    Type: Grant
    Filed: January 27, 2003
    Date of Patent: April 1, 2008
    Assignee: University Court of the University of Aberdeen
    Inventors: Christopher John Secombes, Olga Pleguezuelos
  • Patent number: 7314915
    Abstract: The present invention relates to novel variants of the fluorescent protein GFP having improved fluorescence properties.
    Type: Grant
    Filed: September 23, 2004
    Date of Patent: January 1, 2008
    Assignee: Fisher BioImage APS
    Inventors: Ole Thastrup, Søren Tullin, Lars Kongsbak Poulsen, Sara Petersen Bjørn
  • Patent number: 7279549
    Abstract: The invention relates to relatively short peptides (termed ?-conotoxins herein), about 10-30 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds.
    Type: Grant
    Filed: July 21, 2004
    Date of Patent: October 9, 2007
    Assignees: The University of Utah Research Foundation, Cognetix, Inc.
    Inventors: Maren Watkins, Baldomero M. Olivera, David R. Hillyard, J. Michael McIntosh, Robert M. Jones
  • Patent number: 7271242
    Abstract: Described is a nucleic acid coding for a protein called “cyplasin” that shows a preferential toxicity to autonomously growing mammalian cells. Cell death induced by this protein differs from both apoptosis and necrosis. An intracellular cell death which occurs when recombinantly preparing cyplasin in cell cultures can be avoided by removal of the secretion signal in the cyplasin sequence. This modification makes it possible to express the cyplasin in a mammalian cell culture which is preferable with regard to the glycosylation pattern of the obtained protein. Thus, the present invention also relates to a method of recombinantly producing a protein in eukaryotic cells, preferably mammalian cells, which is cytotoxic for said cells when applied externally.
    Type: Grant
    Filed: December 18, 2002
    Date of Patent: September 18, 2007
    Assignee: Cyplasin Biomedical, Ltd.
    Inventor: Christian Petzelt
  • Patent number: 7179793
    Abstract: An anti-hypertensive fish protein hydrolysate is provided, wherein the fish is of the genus Salmo or Oncorhynchus, and wherein the fish protein hydrolysate comprises at least 1 peptide selected from the group consisting of: Leu-Ala-Phe, Leu-Thr-Phe, Ile-Ile-Phe, Leu-Ala-Tyr, Ile-Ala-Tyr, Val-Phe-Tyr, Tyr-Ala-Tyr, Val-Leu-Trp, Ile-Ala-Trp, Tyr-Ala-Leu and Tyr-Asn-Arg. Methods of making and methods for using such fish protein hydrolysates are also provided.
    Type: Grant
    Filed: February 14, 2005
    Date of Patent: February 20, 2007
    Assignee: Ocean Nutrition Canada Limited
    Inventors: Harry Stephen Ewart, Dorothy Anne Dennis, Colin Barrow, Michael Anthony Potvin
  • Patent number: 7138488
    Abstract: Polypeptides of A1-Arg-A2-Cys-Tyr-A3-A4-X-A5-A6-Cit Cys-A7 (I) or their salts (wherein A1 is hydrogen or a residue of arginine, lysine, ornithine, citrulline, alanine, or the like; A2 is an aromatic amino acid residue; A3, A4 and A6 are each a residue of arginine, lysine, ornithine, citrulline, or alanine; A5 is a residue of tyrosine, phenylalanine, alanine, naphthylalanine, or citrulline; A7 is a lysine or arginine residue whose carboxyl group may be converted into amido; and X is a residue of D-ornithyl-proline, prolyl-D-ornithine, D-lysylproline, or the like, with the proviso that any one of A1, A3, A4, A5, A6 and A7 is a residue of alanine or the like or that X is citrulline or the like).
    Type: Grant
    Filed: September 5, 2001
    Date of Patent: November 21, 2006
    Assignee: Biokine Therapeutics Ltd.
    Inventor: Nobutaka Fujii
  • Patent number: 7128921
    Abstract: The present invention relates to high molecular weight Dermatophagoides proteins, nucleic acid molecules encoding such proteins, and therapeutic and diagnostic reagents derived from such proteins.
    Type: Grant
    Filed: September 14, 2000
    Date of Patent: October 31, 2006
    Assignee: Heska Corporation
    Inventors: Catherine A. McCall, Shirley Wu Hunter, Eric R. Weber
  • Patent number: 6958385
    Abstract: Novel bioactive peptide compositions and process for producing the same and the use of such compositions for enhancing the growth of warm blooded animals and fish is disclosed.
    Type: Grant
    Filed: April 12, 2002
    Date of Patent: October 25, 2005
    Assignee: Biotec Pharmacon ASA
    Inventors: Jan Raa, Gunnar Rorstad
  • Patent number: 6916908
    Abstract: The use of CCH-A subunit isolated from hemocyanin of the marine gastropod Concholepas concholepas (CCH), or a combination thereof, as an immunostimulant agent in the innate or adaptive immune response of vertebrates or as an immunotherapeutic agent in cancer of either humans or animals, where the CCH-A subunit has a molecular weight of about 404 kDa, is stable in the absence of Ca+2 and Mg+2 and is at least 95% pure.
    Type: Grant
    Filed: July 21, 2003
    Date of Patent: July 12, 2005
    Inventors: Alfredo Emilio De Ioannes, Mar{dot over (i)}a Inés Becker
  • Patent number: 6905704
    Abstract: Peptide SY is produced by applying a mixture of peptides obtained by processing fish meat with a protease to a peptide-adsorbing resin (ODS resin or the like), eluting this with water, then with a 11 to 18% v/v ethanol aqueous solution and further with water, and collecting and mixing a latter fraction of the water elution (1), a fraction of the 11 to 18 % v/v ethanol elution and a fraction of the water elution (2). Further, peptide SY-MD is produced by isolating only the fraction of the 11 to 18% v/v ethanol elution. Peptide SY and peptide SY-MD are both novel peptide mixtures. They not only contain a large amount of blood pressure-depressing peptide Val-Tyr newly found but also have less bitterness and are excellent in taste and stability, and can be used as a blood pressure-depressing agent or as functional foods for inhibiting blood pressure elevation or preventing blood pressure elevation.
    Type: Grant
    Filed: December 24, 2002
    Date of Patent: June 14, 2005
    Assignee: Senmi Ekisu Co., Ltd.
    Inventors: Katsuhiro Osajima, Yasunori Ooishi
  • Patent number: 6747001
    Abstract: Novel bioactive peptide compositions and process for producing the same and the use of such compositions for enhancing the growth of warm blooded animals and fish is disclosed.
    Type: Grant
    Filed: May 14, 2001
    Date of Patent: June 8, 2004
    Assignee: BioTec ASA
    Inventors: Jan Raa, Gunnar Rorstad
  • Publication number: 20040081703
    Abstract: The present invention relates to cartilage extracts and to a method of producing the same. Shark cartilage extracts having anti-angiogenic, anti-tumor, anti-inflammatory and anti-collagenolytic activities have been obtained by an improved process. The process comprises the steps of obtaining a crude cartilage extract in an aqueous solution, this crude extract being fractionated to recover molecules of a molecular weight less than about 500 kDa. Some of the biologically active components of the extract are prepared by further fractionation. The cartilage extract can be used for treating diseases or conditions having etiological components selected from the group consisting of tumor proliferation, angiogenesis, inflammation, metalloprotease activity and collagenolysis. Several cosmetic applications based on the capacity of the liquid extract to improve skin conditions are also disclosed. A simple and efficient process for the preparation of cartilage extracts is also disclosed.
    Type: Application
    Filed: October 17, 2003
    Publication date: April 29, 2004
    Applicant: Les Laboratoires Aeterna, Inc.
    Inventors: Eric Dupont, Paul Brazeau, Christina Juneau, Daniel H. Maes, Kenneth Marenus, Richard Beliveau
  • Patent number: 6683161
    Abstract: The present invention relates to a novel human Ependymin protein which is a member of the ependymin family. In particular, isolated nucleic acid molecules are provided encoding the human Ependymin protein. Ependymin polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of Ependymin activity. Also provided are diagnostic methods for detecting nervous system-related disorders and therapeutic methods for treating nervous system-related disorders.
    Type: Grant
    Filed: July 3, 2002
    Date of Patent: January 27, 2004
    Assignee: Human Genome Sciences, Inc.
    Inventors: Reinhard Ebner, Steven M. Ruben
  • Patent number: 6635285
    Abstract: The present invention relates to cartilage extracts and to a method of producing the same. Shark cartilage extracts having anti-angiogenic, anti-tumor, anti-inflammatory and anti-collagenolytic activities have been obtained by an improved process. The process comprises the steps of obtaining a crude cartilage extract in an aqueous solution, this crude extract being fractionated to recover molecules of a molecular weight less than about 500 kDa. Some of the biologically active components of the extract are prepared by further fractionation. The cartilage extract can be used for treating diseases or conditions having etiological components selected from the group consisting of tumor proliferation, angiogenesis, inflammation, metalloprotease activity and collagenolysis. Several cosmetic applications based on the capacity of the liquid extract to improve skin conditions are also disclosed. A simple and efficient process for the preparation of cartilage extracts is also disclosed.
    Type: Grant
    Filed: February 7, 2002
    Date of Patent: October 21, 2003
    Assignee: Les Laboratoires Aeterna, Inc.
    Inventors: Éric Dupont, Paul Brazeau, Christina Juneau, Daniel H. Maes, Kenneth Marenus, Richard Béliveau
  • Patent number: 6475792
    Abstract: The invention relates to methods, compositions and kits for improving the raising of pre-adult anadromous fish, or preparing pre-adult anadromous fish for transfer to seawater. The methods involve adding PVCR modulators (e.g., calcium and/or magnesium) to the freshwater in an amount sufficient to increase expression and/or sensitivity of at least one PVCR; and adding feed for fish consumption to the freshwater, wherein the feed comprises amounts of NaCl and an amino acid sufficient to contribute to a significantly increased level of the PVCR modulator in serum of the pre-adult anadromous fish.
    Type: Grant
    Filed: October 12, 2000
    Date of Patent: November 5, 2002
    Assignee: MariCal, LLC
    Inventors: H. William Harris, Jr., David R. Russell, Jacqueline Nearing, Marlies Betka
  • Patent number: 6417173
    Abstract: The present invention relates to the discovery that biocompatible anionic polymers can effectively inhibit fibrosis, scar formation, and surgical adhesions. The invention is predicated on the discovery that anionic polymers effectively inhibit invasion of cells associated with detrimental healing processes, and in particular, that the effectiveness of an anionic polymer at inhibiting cell invasion correlates with the anionic charge density of the polymer. Thus the present invention provides a large number of materials for use in methods of inhibiting fibrosis and fibroblast invasion. Anionic polymers for use in the invention include but are not limited to natural proteoglycans, and the glycosaminoglycan moieties of proteoglycans. Additionally, anionic carbohydrates and other anionic polymers may be used. The anionic polymers dextran sulfate and pentosan polysulfate are preferred. In a more preferred embodiment, dextran sulfate, in which the sulfur content is greater than about 10% by weight, may be used.
    Type: Grant
    Filed: December 30, 1999
    Date of Patent: July 9, 2002
    Assignee: Gliatech, Inc.
    Inventors: Dikla Roufa, Adrian Harel, Robert C. A. Frederickson, George T. Coker, III
  • Patent number: 6391861
    Abstract: The subject invention is directed to the prevention of elastic fiber injury by administering HA or any other polysaccharide or carbohydrate moiety that binds to and coats elastic fibers, thereby preventing enzymes, oxidants, or other injurious agents from contacting and damaging these fibers. The method may be used to prevent elastic fiber damage which occurs to the skin and blood vessels as a consequence of aging, to the uterus during pregnancy, and in diseases such as pulmonary emphysema, aortic aneurysm, and joint disease. The treatment is intended for humans and a variety of other mammals. The polysaccharide or carbohydrate moiety may be administered orally, cutaneously, subcutaneously, intravenously, intratracheally, or by any other route deemed efficacious. It may be administered alone or in combination with another polysaccharide or carbohydrate moiety, with or without a carrier such as saline solution, DMSO, alcohol or water.
    Type: Grant
    Filed: May 14, 1998
    Date of Patent: May 21, 2002
    Assignee: The Trustees of Columbia University in the City of New York
    Inventor: Jerome O. Cantor
  • Patent number: 6384200
    Abstract: Endotoxin binding/neutralizing proteins capable of binding endotoxin in vivo, thereby neutralizing the toxic effect or bioactivity of endotoxin which are isolated from a horseshoe crab such as Limulus polyphemus, pharmaceutical compositions and pharmaceutical uses of the proteins, a method of purifying the proteins and an assay for endotoxin based on the proteins, are disclosed.
    Type: Grant
    Filed: May 1, 1997
    Date of Patent: May 7, 2002
    Assignee: Associates of Cape Cod, Inc.
    Inventors: Norman R. Wainwright, Thomas J. Novitsky
  • Patent number: 6376650
    Abstract: Novel bioactive peptide compositions and process for producing the same and the use of such compositions for enhancing the growth of warm blooded animals and fish is disclosed.
    Type: Grant
    Filed: April 16, 1998
    Date of Patent: April 23, 2002
    Assignee: Biotec ASA
    Inventors: Jan Raa, Gunnar Rorstad
  • Patent number: 6335430
    Abstract: The invention relates to a process of producing MAP-products from mussel feet. The process is characterised by extracting the mussel feet in a weakly acid aqueous solution containing, for instance, 1-10 percent by weight of a weak acid and 0.5-3 percent by weight of perchloric acid, whereafter the proteins in the aqueous solution are precipitated by adding inorganic or organic salts and separated from the system, subsequent to having extracted the solid substances.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: January 1, 2002
    Inventor: Magnus Qvist
  • Patent number: 6156519
    Abstract: A (1.fwdarw.3)-.beta.-D-glucan binding protein obtainable by affinity chromatography or gel filtration of an extract of horseshoe crab amoebocytes and having a molecular weight of about 580 kDa, as determined by gel filtration under non-reducing conditions, and about 170 kDa, as determined by SDS-PAGE under reducing conditions, is provided.An antibody which selectively recognizes the protein is also provided. Methods for detecting or removing (1.fwdarw.3)-.beta.-D-glucan in or from a sample using the protein and antibody are disclosed.
    Type: Grant
    Filed: June 2, 1997
    Date of Patent: December 5, 2000
    Assignee: Seikagaku Corporation
    Inventors: Hiroshi Tamura, Shigenori Tanaka
  • Patent number: 6153738
    Abstract: The present invention is directed to contryphan peptides having 6-12 amino acids, preferably including one or more D-tryptophan or D-leucine residues. The peptides of the present invention are generically termed "contryphans," although the D-leucine containing contryphans are sometimes referred to as leu-contryphans. More specifically, the present invention is directed to contryphan peptides having the general formula Xaa.sub.1 -Cys-Xaa.sub.2 -Xaa.sub.3 -Xaa.sub.4 -Pro-Xaa.sub.5 -Cys (SEQ ID NO:1), wherein Xaa.sub.1 is any amino acid or des-Xaa.sub.1, Xaa.sub.2 is Pro, 4-trans-hydroxyproline or Val, Xaa.sub.3 is D-Trp, L-Trp, D-Leu or L-Leu, preferably D-Trp or D-Leu, Xaa.sub.4 is any amino acid and Xaa.sub.5 is Trp or Tyr. When the peptide contains Xaa.sub.1, it is preferably Gly, Glu, or Lys, most preferably Gly. When Xaa.sub.3 is D- or L-Trp, Xaa.sub.2 is preferably Pro or 4-trans-hydroxyproline. When Xaa.sub.3 is D- or L-Leu, Xaa.sub.2 is preferably Val.
    Type: Grant
    Filed: December 21, 1999
    Date of Patent: November 28, 2000
    Assignee: University of Utah Research Foundation
    Inventors: Richard Jacobsen, Elsie Jimenez, Lourdes J. Cruz, Baldomero M. Olivera, William R. Gray, Michelle Grilley, Maren Watkins, David R. Hillyard
  • Patent number: 6153731
    Abstract: Dehydrodidemnin B with useful biological activity has formula (1). It can be isolated from natural sources or synthesized, and it forms active derivatives.
    Type: Grant
    Filed: October 30, 1998
    Date of Patent: November 28, 2000
    Assignee: Pharma Mar, s.a.
    Inventors: Kenneth L. Rinehart, Anna M. Lithgow-Bertelloni
  • Patent number: 6127348
    Abstract: The present invention relates to the discovery that biocompatible anionic polymers can effectively inhibit fibrosis, scar formation, and surgical adhesions. The invention is predicated on the discovery that anionic polymers effectively inhibit invasion of cells associated with detrimental healing processes, and in particular, that the effectiveness of an anionic polymer at inhibiting cell invasion correlates with the anionic charge density of the polymer. Thus the present invention provides a large number of materials for use in methods of inhibiting fibrosis and fibroblast invasion. Anionic polymers for use in the invention include but are not limited to natural proteoglycans, and the glycosaminoglycan moieties of proteoglycans. Additionally, anionic carbohydrates and other anionic polymers may be used. The anionic polymers dextran sulfate and pentosan polysulfate are preferred. In a more preferred embodiment, dextran sulfate, in which the sulfur content is greater than about 10% by weight, may be used.
    Type: Grant
    Filed: September 1, 1999
    Date of Patent: October 3, 2000
    Assignee: Gliatech, Inc.
    Inventors: Dikla Roufa, Adrian Harel, Robert C. A. Frederickson, George T. Coker, III
  • Patent number: 6083930
    Abstract: The present invention relates to the discovery that biocompatible anionic polymers can effectively inhibit fibrosis, scar formation, and surgical adhesions. The invention is predicated on the discovery that anionic polymers effectively inhibit invasion of cells associated with detrimental healing processes, and in particular, that the effectiveness of an anionic polymer at inhibiting cell invasion correlates with the anionic charge density of the polymer. Thus the present invention provides a large number of materials for use in methods of inhibiting fibrosis and fibroblast invasion. Anionic polymers for use in the invention include but are not limited to natural proteoglycans, and the glycosaminoglycan moieties of proteoglycans. Additionally, anionic carbohydrates and other anionic polymers may be used. The anionic polymers dextran sulfate and pentosan polysulfate are preferred. In a more preferred embodiment, dextran sulfate, in which the sulfur content is greater than about 10% by weight, may be used.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: July 4, 2000
    Assignee: Gliatech Inc.
    Inventors: Dikla Roufa, Adrian Harel, Robert C. A. Frederickson
  • Patent number: 6020326
    Abstract: The present invention relates to the discovery that biocompatible anionic polymers can effectively inhibit fibrosis, scar formation, and surgical adhesions. The invention is predicated on the discovery that anionic polymers effectively inhibit invasion of cells associated with detrimental healing processes, and in particular, that the effectiveness of an anionic polymer at inhibiting cell invasion correlates with the anionic charge density of the polymer. Thus the present invention provides a large number of materials for use in methods of inhibiting fibrosis and fibroblast invasion. Anionic polymers for use in the invention include but are not limited to natural proteoglycans, and the glycosaminoglycan moieties of proteoglycans. Additionally, anionic carbohydrates and other anionic polymers may be used. The anionic polymers dextran sulfate and pentosan polysulfate are preferred. In a more preferred embodiment, dextran sulfate, in which the sulfur content is greater than about 10% by weight, may be used.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: February 1, 2000
    Assignee: Gliatech Inc.
    Inventors: Dikla Roufa, Adrian Harel, Robert C.A. Frederickson, George T. Coker, III
  • Patent number: 6007811
    Abstract: The present invention is a fibrin sealant and a method for producing a fibrin sealant from fish blood. Whole blood is drawn from the donor fish and centifuged to separate blood cells from plasma. Prothrombin and fibrinogen are extracted from this plasma, and the prothrombin is activated to thrombin. The fibrinogen and thrombin components are then combined as needed to form the fibrin sealant.
    Type: Grant
    Filed: July 1, 1998
    Date of Patent: December 28, 1999
    Assignee: Sea Run Holdings, Inc.
    Inventors: Evelyn S. Sawyer, Philip J. Sawyer, Jed B. Gorlin, Paul A. Jamney
  • Patent number: 5994325
    Abstract: The present invention relates to the discovery that biocompatible anionic polymers can effectively inhibit fibrosis, scar formation, and surgical adhesions. The invention is predicated on the discovery that anionic polymers effectively inhibit invasion of cells associated with detrimental healing processes, and in particular, that the effectiveness of an anionic polymer at inhibiting cell invasion correlates with the anionic charge density of the polymer. Thus the present invention provides a large number of materials for use in methods of inhibiting fibrosis and fibroblast invasion. Anionic polymers for use in the invention include but are not limited to natural proteoglycans, and the glycosaminoglycan moieties of proteoglycans. Additionally, anionic carbohydrates and other anionic polymers may be used. The anionic polymers dextran sulfate and pentosan polysulfate are preferred. In a more preferred embodiment, dextran sulfate, in which the sulfur content is greater than about 10% by weight, may be used.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: November 30, 1999
    Assignee: Gliatech Inc.
    Inventors: Dikla Roufa, Adrian Harel, Robert C. A. Frederickson, George T. Coker, III
  • Patent number: 5965534
    Abstract: The invention is directed to the use of .omega.-conotoxins for the prevention and treatment of retinal or optic nerve head damage in humans. Compositions and methods are disclosed.
    Type: Grant
    Filed: March 13, 1998
    Date of Patent: October 12, 1999
    Assignee: Alcon Laboratories, Inc.
    Inventors: Iok-Hou Pang, Michael Kapin, Mark Hellberg
  • Patent number: 5958248
    Abstract: A method and a system which enable simple and inexpensive removal of heavy metals from a heavy-metal-containing substance. In this method, a substance containing heavy metals and water are introduced into a mixing bath in proportions by weight of 1:3 to 1:6. A strong acid is added to the mixture, and the mixture is stirred while its pH is maintained at a pH lower than 4. As a result of stirring of the substance at a pH 4, heavy metals are extracted into the liquid as metal ions. The metal-ion-containing liquid is input to a heavy metal precipitation bath, and the pH of the liquid is increased to a pH higher than 10 by addition of alkali to the liquid. Gas bubbles of carbonic acid gas are input to the liquid from a lower portion of the heavy metal precipitation bath, and they are broken into a large quantity of small gas bubbles of carbonic acid gas by turbine blades. The large quantity of gas bubbles of carbonic acid are brought into contact with the metal-ion-containing liquid having a pH higher than 10.
    Type: Grant
    Filed: August 1, 1997
    Date of Patent: September 28, 1999
    Inventor: Yukimasa Satoh
  • Patent number: 5866682
    Abstract: This invention relates to relatively short peptides about 14-17 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogs to the naturally available peptides, and which include two cyclizing disulfide linkages. More specifically, the present invention is directed to conopeptides having the general formula: Gly-Cys-Cys-Ser-Tyr-Xaa.sub.1 -Xaa.sub.1 -Cys-Phe-Ala-Thr-Asn-Xaa.sub.2 -Xaa.sub.3 -Xaa.sub.4 -Cys (SEQ ID NO: 1), wherein Xaa.sub.1 is Pro or Hyp (trans-4-hydroxy-Pro), Xaa.sub.2 is Ser, Pro or Hyp, Xaa.sub.3 is Gly or Asp and Xaa.sub.4 is a Tyr or des- Xaa.sub.4. The disulfide bridges are between the first and third between the second fourth cysteine residues. The C-terminal end is preferably amidated.
    Type: Grant
    Filed: May 15, 1997
    Date of Patent: February 2, 1999
    Assignee: University of Utah Research Foundation
    Inventors: J. Michael McIntosh, G. Edward Cartier, Doju Yoshikami, Siqin Luo, Baldomero M. Olivera
  • Patent number: 5780429
    Abstract: This invention is directed to pharmaceutical and cosmetic compositions comprising anti-lipopolysaccharide (anti-LPS) factor proteins derived from horseshoe crabs, either in the native form or produced by recombinant means. The pharmaceutical formulations, which may include anti-LPS factor proteins alone or in combination with other antimicrobials, may be used in the treatment of gram-negative bacterial infections, endotoxemia, septic shock, gram-positive bacterial infections, and yeast infections. The anti-LPS factor protein-containing pharmaceuticals can be formulated for systemic or topical administration. They may also be used to control mold growth. Anti-LPS factor proteins can be used in cosmetic compositions or skin or hair preparations as antimicrobial preservatives, either alone or in combination with conventional preservatives, to prevent or control the growth of bacteria, yeast and mold.
    Type: Grant
    Filed: December 22, 1995
    Date of Patent: July 14, 1998
    Assignee: Marine Biological Laboratory
    Inventor: Norman R. Wainwright
  • Patent number: 5770560
    Abstract: The invention relates to the use of fish hemoglobins that exhibit a Root effect to increase tissue oxygenation in patients suffering from disease states associated with compromised oxygen delivery to tissues.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: June 23, 1998
    Assignee: James J. Fischer
    Inventors: James J. Fischer, Susan J. Baserga
  • Patent number: 5747322
    Abstract: An isolated sequence is provided that encodes crab procollagenase (Seq ID NO 5) that upon cleaving off the 29 amino acid propeptide (Seq ID NO 6) transforms into an active collagenase (Seq ID NO 4). The procollagenase has the MW of about 26.6 kD and the mature collagenase has a MW of 23.5 kD. Procollagenase mutated at positions 201 and 235 is also provided. A storage-stabilized composition providing long-term, shelf-stable protease that can be readily activated when collagenolytic activity is desired is disclosed.
    Type: Grant
    Filed: May 9, 1996
    Date of Patent: May 5, 1998
    Assignee: The Regents of the University of California
    Inventors: Charles S. Craik, Christopher A. Tsu
  • Patent number: 5747455
    Abstract: Endotoxin binding/neutralizing proteins capable of binding endotoxin in vivo, thereby neutralizing the toxic effect or bioactivity of endotoxin which are isolated from a horseshoe crab such as Limulus polyphemus, pharmaceutical compositions and pharmaceutical uses of the proteins, a method of purifying the proteins and an assay for endotoxin based on the proteins, are disclosed.
    Type: Grant
    Filed: August 30, 1996
    Date of Patent: May 5, 1998
    Assignee: Associates of Cape Cod, Inc.
    Inventors: Norman R. Wainwright, Thomas J. Novitsky
  • Patent number: 5703211
    Abstract: The present invention relates to a process for preparing collagen finings. The process comprises providing collagen in the form of undried fish isinglass which has been freshly prepared or frozen, substantially in the absence of any pre-drying, and hydrolyzing the isinglass under conditions to solubilize the collagen. By using freshly-prepared or frozen isinglass, the irreversible changes to collagen arising from pre-drying of isinglass are largely avoided.
    Type: Grant
    Filed: March 16, 1995
    Date of Patent: December 30, 1997
    Inventor: Robert Taylor
  • Patent number: 5633347
    Abstract: The invention is directed to A-lineage conotoxin peptides, which are conotoxin peptides that have strong homology in the signal sequence and the 3'-untranslated region of the genes coding for these peptides to the sequences in the .alpha.-conotoxin peptides. The A-lineage conotoxin peptides include the .alpha.-conotoxin peptides, the .alpha.-conotoxin-like peptides and the .kappa.-conotoxin peptides, described further below. The .alpha.-conotoxin-peptides generally share a "core" sequence motif. This core sequence is termed the .alpha.3/5 core and is represented as Cys-Cys-Xaa-Xaa-Xaa- Cys-Xaa-Xaa-Xaa-Xaa-Xaa-Cys (SEQ ID NO:1). The .alpha.-conotoxin-like peptides generally share a core sequence termed the .alpha.4/7 core and is represented as Cys-Cys-Xaa-Xaa-Xaa-Xaa-Cys-Xaa- Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Cys (SEQ ID NO:2). The .kappa.-conotoxin peptides generally have a core sequence termed the .kappa.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: May 27, 1997
    Assignee: University of Utah Research Foundation
    Inventors: Baldomero M. Olivera, Lourdes J. Cruz, David R. Hillyard, J. Michael McIntosh, Ameurfino O. Santos
  • Patent number: 5618725
    Abstract: Biodegradation additive characterized in that it consists of a mixture of (i) at least one assimilable nitrogen source composed of at least one unsubstituted or substituted amino acid; (ii) at least one phosphorus source, the ratio of nitrogen to phosphorus ranging from 2 to 100, said additive being subjected to a treatment to make it oleophilic. The invention also concerns an additive in accordance with any of the foregoing claims for the biodegradation of hydrocarbons.
    Type: Grant
    Filed: May 8, 1995
    Date of Patent: April 8, 1997
    Assignee: Elf Aquitaine
    Inventors: Anne Basseres, Patrick Eyraud, Alain Ladousse
  • Patent number: 5605938
    Abstract: The present invention relates to the discovery that biocompatible anionic polymers can effectively inhibit fibrosis, scar formation, and surgical adhesions. The invention is predicated on the discovery that anionic polymers effectively inhibit invasion of cells associated with detrimental healing processes, and in particular, that he effectiveness of an anionic polymer at inhibiting cell invasion correlates with the anionic charge density of the polymer. Thus the present invention provides a large number of materials for use in methods of inhibiting fibrosis and fibroblast invasion. Anionic polymers for use in the invention include but are not limited to natural proteoglycans, and the glycosaminoglycan moieties of proteoglycans. Additionally, anionic carbohydrates and other anionic polymers may be used. The anionic polymers dextran sulfate and pentosan polysulfate are preferred. In a more preferred embodiment, dextran sulfate, in which the sulfur content is greater than about 10% by weight, may be used.
    Type: Grant
    Filed: May 31, 1991
    Date of Patent: February 25, 1997
    Assignee: Gliatech, Inc.
    Inventors: Dikla Roufa, Adrian Harel, Robert C. A. Frederickson, George T. Coker, III
  • Patent number: 5594113
    Abstract: Endotoxin binding/neutralizing proteins capable of binding endotoxin in vivo, thereby neutralizing the toxic effect or bioactivity of endotoxin which are isolated from a horseshoe crab such as Limulus polyphemus, pharmaceutical compositions and pharmaceutical uses of the proteins, a method of purifying the proteins and an assay for endotoxin based on the proteins, are disclosed.
    Type: Grant
    Filed: June 22, 1994
    Date of Patent: January 14, 1997
    Assignee: Associates of Cape Cod, Inc.
    Inventors: Norman R. Wainwright, Thomas J. Novitsky